Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Yuhan Corporation

http://eng.yuhan.co.kr/Main/

Latest From Yuhan Corporation

What Will Drive Korean Pharma's Next Decade Of Growth?

A recent event in South Korea heard one prominent investor advise South Korean pharma firms to sharply increase their new drug R&D and seek direct entry into global markets, rather than pursuing licensing deals for growth

South Korea Deals

Korean Pharmas Seek Tie-Ups, Support To Enter Pharmerging Markets

Through its latest government-linked project, Korean pharma consortium Kimco aims to speed up industry collaboration and step up technology competitiveness to move into rapidly growing pharmerging markets.

South Korea Research and Development Strategies

Asia Deal Watch: Vibegron’s Vagabond Journey Continues With Eisai Acquiring Partial Asian Rights

Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio

Deals M & A

COVID-19 Accounts For Most Of 2020’s Pharma Pipeline Growth

The impact of the coronavirus pandemic on the size of the pharma R&D pipeline in 2020 could be felt in a number of ways.

Companies Research & Development
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • Yuhan USA
UsernamePublicRestriction

Register